tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ATXS Stock Latest News

Astria Therapeutics: Strategic Partnership and Promising Phase 3 Trial Justify Buy Rating
RatingsAstria Therapeutics: Strategic Partnership and Promising Phase 3 Trial Justify Buy Rating
10h ago
ATXS
Astria Therapeutics’ Strategic Advancements and Market Potential: A Buy Recommendation by Joseph Pantginis
PremiumRatings
Astria Therapeutics’ Strategic Advancements and Market Potential: A Buy Recommendation by Joseph Pantginis
11h ago
ATXS
Astria Therapeutics licenses navenibart rights in Japan to Kaken Pharmaceutical
PremiumThe Fly
Astria Therapeutics licenses navenibart rights in Japan to Kaken Pharmaceutical
13h ago
ATXS
Astria Therapeutics Enters Licensing Deal with Kaken
PremiumCompany Announcements
Astria Therapeutics Enters Licensing Deal with Kaken
14h ago
8K
ATXS
Promising Developments and Consistent Performance Drive Buy Rating for Astria Therapeutics
PremiumRatings
Promising Developments and Consistent Performance Drive Buy Rating for Astria Therapeutics
2M ago
ATXS
Astria announces initial results from ALPHA-SOLAR target enrollment group
PremiumThe FlyAstria announces initial results from ALPHA-SOLAR target enrollment group
2M ago
ATXS
Astria Therapeutics Stockholders Approve Key Amendments
Premium
Company Announcements
Astria Therapeutics Stockholders Approve Key Amendments
2M ago
8K
ATXS
Astria Therapeutics: Favorable Market Position Amid Competitor Safety Concerns
Premium
Ratings
Astria Therapeutics: Favorable Market Position Amid Competitor Safety Concerns
2M ago
ATXS
Astria Therapeutics Reports Increased Loss Amid Rising R&D Costs
PremiumCompany Announcements
Astria Therapeutics Reports Increased Loss Amid Rising R&D Costs
3M ago
ATXS
Positive Outlook for Astria Therapeutics: Buy Rating Driven by Promising Clinical Developments and Strategic Focus
PremiumRatings
Positive Outlook for Astria Therapeutics: Buy Rating Driven by Promising Clinical Developments and Strategic Focus
3M ago
ATXS
Buy Rating for Astria Therapeutics Driven by Promising Clinical Developments and Strong Financial Position
PremiumRatings
Buy Rating for Astria Therapeutics Driven by Promising Clinical Developments and Strong Financial Position
3M ago
ATXS
Astria Therapeutics price target lowered to $25 from $26 at Citizens JMP
PremiumThe Fly
Astria Therapeutics price target lowered to $25 from $26 at Citizens JMP
3M ago
ATXS
Astria Therapeutics reports Q1 EPS (58c), consensus (48c)
PremiumThe FlyAstria Therapeutics reports Q1 EPS (58c), consensus (48c)
3M ago
ATXS
ATXS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ATXS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
ATXS
Chord, InMode, Upstart, BridgeBio, Astria: Trending by Analysts
Premium
Weekend Updates
Chord, InMode, Upstart, BridgeBio, Astria: Trending by Analysts
3M ago
ATXS
BBIO
Astria Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Astria Therapeutics initiated with an Overweight at Cantor Fitzgerald
3M ago
ATXS
Astria Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Astria Therapeutics initiated with an Overweight at Cantor Fitzgerald
3M ago
ATXS
Astria Therapeutics price target raised to $28 from $27 at Wedbush
PremiumThe Fly
Astria Therapeutics price target raised to $28 from $27 at Wedbush
5M ago
ATXS
Astria Therapeutics Advances Clinical Trials and Financials
PremiumCompany Announcements
Astria Therapeutics Advances Clinical Trials and Financials
5M ago
ATXS
Astria Therapeutics: Promising Developments and Strategic Advancements Justify Buy Rating
PremiumRatingsAstria Therapeutics: Promising Developments and Strategic Advancements Justify Buy Rating
5M ago
ATXS
Astria Therapeutics: Promising Pipeline and Strong Financials Drive Buy Rating
Premium
Ratings
Astria Therapeutics: Promising Pipeline and Strong Financials Drive Buy Rating
5M ago
ATXS
Buy Rating for Astria Therapeutics: Promising Clinical Advancements and Strong Financial Position
Premium
Ratings
Buy Rating for Astria Therapeutics: Promising Clinical Advancements and Strong Financial Position
5M ago
ATXS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >